<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CD120AEA-FB8C-4583-B0C3-A460490BE9F3"><gtr:id>CD120AEA-FB8C-4583-B0C3-A460490BE9F3</gtr:id><gtr:firstName>Dimitri</gtr:firstName><gtr:otherNames>Michael</gtr:otherNames><gtr:surname>Kullmann</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/53323344-3564-46B0-BF9D-68BCA2496856"><gtr:id>53323344-3564-46B0-BF9D-68BCA2496856</gtr:id><gtr:firstName>Parmjit</gtr:firstName><gtr:surname>Jat</gtr:surname><gtr:orcidId>0000-0002-3354-0594</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/25A55E6B-3FCD-4B79-AE52-D49CE4138B7E"><gtr:id>25A55E6B-3FCD-4B79-AE52-D49CE4138B7E</gtr:id><gtr:firstName>Stephanie</gtr:firstName><gtr:surname>Schorge</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601440"><gtr:id>5B8E0D27-937E-4B4D-9C3A-C32E3927EF5A</gtr:id><gtr:title>The role of persistent currents generated by sodium channel splicing in neurological disorders</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601440</gtr:grantReference><gtr:abstractText>Neurons in the brain communicate using electrical signals. These signals are generated by a particular set of molecules called sodium channels. Many drugs used to treat neurological illnesses, such as epilepsy and chronic pain, bind to sodium channels. These drugs do not simply block the channels (that would be fatal to the patient). Instead they allow the channels to make the electrical signals, but they ensure that in between the signals the channels are firmly closed. We have discovered that the genes that code for sodium channels can often be read in two alternate ways in order to make two slightly different channels from each gene. These different channels are called splice variants, because they are made by splicing the genes differently. We have shown that the splice variants from one gene are much more likely to open in between electrical signals, and consequently they may be the most important target of many drugs. 
We have also found that some diseases, such as epilepsy, cause the sodium channel genes to generate more of the splice variants that open between electrical signals. This means the disease itself may lead to neurons in the brain having more of these channels that require drugs to keep closed between signals. Many diseases are thought to change the number of channels that open between signals, including Parkinson s disease, motor neurone disease and neuropathic pain, as well as epilepsy. We ask whether any or all of these diseases change the amount of sodium channel splice variants, and whether these sodium channel splice variants may represent a more specific target for drugs that would produce fewer side effects than drugs that affect all sodium channel splice variants. 
By looking at the behaviour of neuronal cells grown in petri dishes, and examining how drugs bind to the sodium channels and how the genes are being spliced we will determine whether the splice variants are specifically targeted by drugs and how removing the splice variants will change the neurons. We will also investigate whether conditions that mimic diseases lead to changes in the splicing. It is possible that by preventing the neurons from making the splice variants that open between electrical signals, we will be able to directly alleviate some of the changes in neuronal behaviour linked to neurological disorders. This may lead to a new approach to treating some of these difficult and persistent disorders.</gtr:abstractText><gtr:technicalSummary>Voltage-gated sodium channels generate the action potentials that define virtually all excitable cells. The rapidly inactivating transient sodium currents from these channels controls the duration of action potentials, but a second type of sodium current, the persistent current, modulates the timing, spacing and threshold of action potentials. Although the persistent current is much smaller in amplitude than the transient current, it has profound effects on neuronal properties. In fact, subtle changes in persistent currents are associated with many mutations in sodium channels that cause inherited epilepsies, and seem to be sufficient to lead to seizures.
The molecular basis of persistent currents remains mysterious. They are modulated by G-protein pathways, but may be generated by the same physical channels that generate transient sodium currents. We have recently shown that a conserved site of alternative splicing in TTX-sensitive sodium channels has dramatic effects on the amount of persistent current one type of channel (SCN1A) produces when heterologously expressed in mammalian cell lines. This alternative splicing is dynamically regulated during development, and also in epilepsy, most likely leading to changes in persistent currents in neurons and their behaviour.
We will ask how this splicing affects closely-related sodium channels, whether the changes in persistent currents seen in other neurological disorders are also associated with changes in splicing, and how directly manipulating the levels of the splice variants in vitro affects neuronal behaviour. We have also recently shown that certain sodium channel beta subunits are capable of masking the effects of alternative splicing in SCN1A, however there is evidence that these beta subunits are down-regulated in the same conditions that promote the splicing that leads to persistent currents. Consequently we will also investigate how the regulation of the beta subunits complements the changes in splicing in the alpha subunits, and whether directly down-regulating the beta subunits will lead to unmasking of low levels of alternatively spliced alpha subunits in otherwise healthy cells. 
We are combining our biophysical, physiological and molecular expertise to approach the question of the regulation, functional impact and consequences of alternative splicing for these important channels. Finally, because the persistent currents are an important target of many drugs that target sodium currents, understanding the nature, generation and regulation of these currents and their link to alternative splicing should provide new insights into drug effects and may provide a more specific target for future drug design.</gtr:technicalSummary><gtr:fund><gtr:end>2010-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>514057</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>DIS visits from students</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>89485C89-1FB6-4A24-B3A6-EA8A8B0C812D</gtr:id><gtr:impact>International undergraduate students (20-30) with the DIS programme in Copenhagen visit ION at Queen Square, hear a presentation and tour the Department, and discuss careers in science with the team.</gtr:impact><gtr:outcomeId>56d581a135faa7.63764229</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015,2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Visit (Lenox)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CB89F12B-9E01-4309-B85D-BCDC45106537</gtr:id><gtr:impact>This was a presentation on Gene Therapy and treatments of epilepsy to a High School audience in the states.</gtr:impact><gtr:outcomeId>56d58120084d72.23193808</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Work experience at ION</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B4A40663-5515-408D-81F5-9C37C15FBDDE</gtr:id><gtr:impact>Both students were well-engaged with basic and clinical research at the Institute of Neurology.

Social Mobility Fund and the Worshipful Company of Pewterers have both indicated they'd be delighted to carry on with the scheme in future years.</gtr:impact><gtr:outcomeId>545cee2167be22.60723829</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Livery Science day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>875F11CB-56F6-45B1-AE49-13166B5E5357</gtr:id><gtr:impact>I arranged a one day 'Introduction to the Hypothesis' which brought UCL post-graduate students to dis-advantaged London schools, to allow children to interact with scientists and to carry out simple experiments to test hypotheses.

We are invited back - and the children love the day, but without the RCUK award, it is difficult to fund. I have much stronger associations with the livery companies, and am now working to arrange fund raising on their behalf for a fellowship.</gtr:impact><gtr:outcomeId>TKztp6HmeVA</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at Royal Society summer science festival</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4340B805-0BCA-42C1-ACD6-8A2CD4F9BD2B</gtr:id><gtr:impact>I gave a presentation &amp;quot;Brain Hacking With Viruses&amp;quot; introducing the concepts of Gene therapy for epilepsy at the Royal Society Summer Science Festival. The talk was repeated 4 times, and was well attended by students from around the UK. I also raised some of the ethical and safety concerns of the approach and got very strong feedback in the questions that students were interested even if the testing involved use of animals in research.</gtr:impact><gtr:outcomeId>58bfdd7415bc71.47016996</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>https://royalsociety.org/science-events-and-lectures/2016/07/schools-talk-schorge-tuesday/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>FP7 grant</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>602130</gtr:fundingRef><gtr:id>8A8E5627-28F3-49A0-AE77-321A92AC64C1</gtr:id><gtr:outcomeId>S9zeoGpJ41K</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>323000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Project Grant</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>086882</gtr:fundingRef><gtr:id>C7D6A2CD-6971-4E6F-A3BF-E032C6F37927</gtr:id><gtr:outcomeId>ZUFcffWrp3m</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>550000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Royal Society Fellowship</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>E7E8F22B-9F8D-4731-8FF3-03A704F89E11</gtr:id><gtr:outcomeId>ofi3NjfU1CP0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2017-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L003457/1</gtr:fundingRef><gtr:id>CAF6CC03-8541-4DEE-AD05-2B2F13141E92</gtr:id><gtr:outcomeId>nU5LwgtHeJh</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Queen Square award for implemenation of 3Rs in Research</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>143D6D53-552C-4221-9FCE-D0A2B521AA7D</gtr:id><gtr:impact>We are working to change our local attitudes towards working with animals in research. We presented this award to the then Cabinet Minister, and it was recognised as a high level local engagement with the 3Rs in animal work. All students presenting their scientific posters at the symposium are now aware that they must also explain their measures to improve 3Rs to our NACWO, including justifying the model used.</gtr:impact><gtr:outcomeId>545cf7b705dfa7.82947698</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of SACGM(CU)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>544A8F26-572C-4B37-B65C-408345D0F084</gtr:id><gtr:outcomeId>XCt38jp2yYa</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Appointed to Epilepsy Research UK Science Advisory Committee</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F0D86814-46F3-400D-B616-BF8D3C77131D</gtr:id><gtr:outcomeId>SerM8N2aJeo</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2F498D84-90E1-4129-A83C-8C191FB92A9B</gtr:id><gtr:title>Episodic ataxia type 1: a neuronal potassium channelopathy.</gtr:title><gtr:parentPublicationTitle>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14632e9fec0b4b9b740218552a278537"><gtr:id>14632e9fec0b4b9b740218552a278537</gtr:id><gtr:otherNames>Rajakulendran S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1878-7479</gtr:issn><gtr:outcomeId>DDD269413AF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45B8C667-04A7-4BA3-8898-28D678F5BA74</gtr:id><gtr:title>Molecular characterisation of post-bio-electrosprayed human brain astrocytoma cells.</gtr:title><gtr:parentPublicationTitle>The Analyst</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ab44c34f732e38c4dd462a6dbcd5c02"><gtr:id>1ab44c34f732e38c4dd462a6dbcd5c02</gtr:id><gtr:otherNames>Eddaoudi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0003-2654</gtr:issn><gtr:outcomeId>rvwnvqg3WX5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E33AB146-933B-42CF-8D8B-F09F17922E7E</gtr:id><gtr:title>From treatment to cure: stopping seizures, preventing seizures, and reducing brain propensity to seize.</gtr:title><gtr:parentPublicationTitle>International review of neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1dfdefb4f074acaad26adccba29954d"><gtr:id>b1dfdefb4f074acaad26adccba29954d</gtr:id><gtr:otherNames>Pavlov I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0074-7742</gtr:issn><gtr:outcomeId>5437e5f4011ba3.17747675</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D6ED077-4222-4ECF-8BAC-ECE19A7D671B</gtr:id><gtr:title>Epileptogenesis is associated with enhanced glutamatergic transmission in the perforant path.</gtr:title><gtr:parentPublicationTitle>Journal of neurophysiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d125671b695fc3cf5aac8307d0ba6e6"><gtr:id>3d125671b695fc3cf5aac8307d0ba6e6</gtr:id><gtr:otherNames>Scimemi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-3077</gtr:issn><gtr:outcomeId>7B6DF8C70F4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D02F9702-1868-47A5-A58B-973E06487B32</gtr:id><gtr:title>Gene therapy in status epilepticus.</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f13d4d30c5a901bebc5dc995df7dfd5b"><gtr:id>f13d4d30c5a901bebc5dc995df7dfd5b</gtr:id><gtr:otherNames>Walker MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>pm_14982_22_24001071</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86248DF2-BEB5-42C0-9A37-57F81C1D2B32</gtr:id><gtr:title>Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86eb63290fdcd11754a77699cac61733"><gtr:id>86eb63290fdcd11754a77699cac61733</gtr:id><gtr:otherNames>Matthews E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>A192BD0A203</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>403D8A71-04BA-467F-8945-E12A591116AF</gtr:id><gtr:title>Chemical-genetic attenuation of focal neocortical seizures.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e71c4ba694ccab7ce7b6754c5c8856a6"><gtr:id>e71c4ba694ccab7ce7b6754c5c8856a6</gtr:id><gtr:otherNames>K?tzel D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5437e5f3c235d0.88252596</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BB53FDC-D52C-45C8-9918-2EE29C8A8405</gtr:id><gtr:title>Nongenetic factors influence severity of episodic ataxia type 1 in monozygotic twins.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86694d88fb2c9bb553f0bfcfc3584548"><gtr:id>86694d88fb2c9bb553f0bfcfc3584548</gtr:id><gtr:otherNames>Graves TD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>f5Q3tcqFCrk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30673436-1089-43F5-A120-E96DA7E76C82</gtr:id><gtr:title>A patient with episodic ataxia and paramyotonia congenita due to mutations in KCNA1 and SCN4A.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14632e9fec0b4b9b740218552a278537"><gtr:id>14632e9fec0b4b9b740218552a278537</gtr:id><gtr:otherNames>Rajakulendran S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>125CB4B327B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>770D4CE9-94A1-4D0D-89D8-14F201EFF1A2</gtr:id><gtr:title>Large scale calcium channel gene rearrangements in episodic ataxia and hemiplegic migraine: implications for diagnostic testing.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3d700fecb67b99136b863c2ea912693"><gtr:id>d3d700fecb67b99136b863c2ea912693</gtr:id><gtr:otherNames>Labrum RW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn><gtr:outcomeId>0E6CEFD3EC5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D39EBA0-B1A4-4C8D-85EF-470D9C8BF6E7</gtr:id><gtr:title>Splice variants of Na(V)1.7 sodium channels have distinct ? subunit-dependent biophysical properties.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ccc2d2b825dc095a461ecde19f7dece"><gtr:id>6ccc2d2b825dc095a461ecde19f7dece</gtr:id><gtr:otherNames>Farmer C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14982_22_22911851</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0298A131-CCBB-4EB7-A118-2108C17ABD36</gtr:id><gtr:title>Episodic ataxia type 1 mutations differentially affect neuronal excitability and transmitter release.</gtr:title><gtr:parentPublicationTitle>Disease models &amp; mechanisms</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95a8882d6b6ca14f034fcc78604f6a4a"><gtr:id>95a8882d6b6ca14f034fcc78604f6a4a</gtr:id><gtr:otherNames>Heeroma JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1754-8403</gtr:issn><gtr:outcomeId>13A56E3D032</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D577A5E-0A66-44FA-A4A7-0BCFD544077A</gtr:id><gtr:title>Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab5d922700c9e9c3deb2ccbcc87b9667"><gtr:id>ab5d922700c9e9c3deb2ccbcc87b9667</gtr:id><gtr:otherNames>Wykes RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>pm_14982_22_23147003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>980BC5C0-6AB4-45B7-B894-DB393A9CDEBB</gtr:id><gtr:title>A common SCN1A splice-site polymorphism modifies the effect of carbamazepine on cortical excitability--a pharmacogenetic transcranial magnetic stimulation study.</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9e9f5f1fb509e920c4fc58537faa76f"><gtr:id>a9e9f5f1fb509e920c4fc58537faa76f</gtr:id><gtr:otherNames>Menzler K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>5437e5f31858a2.02430499</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>041D4645-89F0-4011-A010-4192C1BC3C6B</gtr:id><gtr:title>Chloride channel myotonia: exon 8 hot-spot for dominant-negative interactions.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ba1bb31dc3adc9eddf6a5a6486279c1"><gtr:id>1ba1bb31dc3adc9eddf6a5a6486279c1</gtr:id><gtr:otherNames>Fialho D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>E9A20700156</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>090491F8-8762-4FA4-92AD-B215668FDCBA</gtr:id><gtr:title>Gene therapy in epilepsy-is it time for clinical trials?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db5860e115fb39bc53662cfaa7f12d6a"><gtr:id>db5860e115fb39bc53662cfaa7f12d6a</gtr:id><gtr:otherNames>Kullmann DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1759-4758</gtr:issn><gtr:outcomeId>5437e5f34d9f47.39236399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E223EEE-3CBA-4117-B525-BE4E08458B47</gtr:id><gtr:title>Non-genomic effects of sex hormones on CLC-1 may contribute to gender differences in myotonia congenita.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ba1bb31dc3adc9eddf6a5a6486279c1"><gtr:id>1ba1bb31dc3adc9eddf6a5a6486279c1</gtr:id><gtr:otherNames>Fialho D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>B6E9E80ED06</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12C3C21E-CCB8-4448-8CF1-6A832BA03C3A</gtr:id><gtr:title>Insights from cerebellar transcriptomic analysis into the pathogenesis of ataxia.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9960cd808582e52821f0e586e2ba9176"><gtr:id>9960cd808582e52821f0e586e2ba9176</gtr:id><gtr:otherNames>Bettencourt C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>5437e5f3880d18.80672444</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E5D4A35-FFCD-4AD4-AE36-9270C2133DB7</gtr:id><gtr:title>Alternative splicing modulates inactivation of type 1 voltage-gated sodium channels by toggling an amino acid in the first S3-S4 linker.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2748097c5a93b216cbf5bf41ebdbb3ad"><gtr:id>2748097c5a93b216cbf5bf41ebdbb3ad</gtr:id><gtr:otherNames>Fletcher EV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>N4ULig5wFmW</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601440</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>